New drug combo targets recurrent brain tumors in early trial
NCT ID NCT04826393
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial tested a combination of two drugs, ASP8374 and cemiplimab (Libtayo), in 14 people with recurrent malignant glioma, a type of brain cancer. The study had two parts: first, finding the safest dose of ASP8374 when given with cemiplimab, and second, checking how the drugs affect immune cells in the tumor before surgery. The goal was to assess safety and immune response, not to cure the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ASP8374 and cemiplimab (Libtayo)
What this could lead to
If it works, this could point toward a new treatment option for recurrent glioblastoma, a type of brain cancer with few effective therapies.
What could go wrong
This is a very early, small phase 1 trial with only 14 participants. It mainly tests safety and dosing, not effectiveness. The drugs may not shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Hospital of the University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States